Emcure Pharmaceuticals Ltd (NSE: EMCURE) and RUBICON RESEARCH LIMITED (NSE: RUBICON) are both listed in the Pharmaceuticals industry. Emcure Pharmaceuticals has a market capitalisation of ₹35,726 Cr and RUBICON RESEARCH ₹27,601 Cr, as of 9 Nov 2026. Their P/E ratios are 38.6 and 108.9 respectively. Return on equity is 19.57% for Emcure Pharmaceuticals and 19.14% for RUBICON RESEARCH. Over one year, Emcure Pharmaceuticals's share price is up 67.0% and RUBICON RESEARCH's is up 186.9%.
| Metric | Emcure Pharmaceuticals | RUBICON RESEARCH |
|---|---|---|
| NSE Symbol | EMCURE | RUBICON |
| BSE Code | 544210 | 544578 |
| Share Price | ₹2,215.00 | ₹1,773.60 |
| Market Cap | ₹35,726 Cr | ₹27,601 Cr |
| P/E Ratio | 38.6 | 108.9 |
| Return on Equity | 19.57% | 19.14% |
| Return on Assets | 9.62% | 11.74% |
| Dividend Yield | 0.19% | 0.09% |
| Beta (1Y) | -0.01 | 0.13 |
| 1-Year Price Change | +67.0% | +186.9% |
| 3-Month Price Change | +11.0% | +11.1% |
| 52-Week Range | ₹1,312.30 – ₹2,280.00 | ₹615.20 – ₹1,899.00 |
| Latest Quarter | Q2 FY27 | Q2 FY27 |
| Quarterly Revenue | ₹2,820 Cr | ₹576 Cr |
| Quarterly Net Profit | ₹325 Cr | ₹90 Cr |
| Net Margin | 11.5% | 15.7% |
| EPS (Basic, Quarter) | ₹17.16 | ₹5.47 |
| Results Basis | consolidated | consolidated |
| Headquarters | Pune, Maharashtra | Mumbai, Maharashtra |
The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.
Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynecology, anti-infectives, pain/analgesics, Vitamins, Minerals & Nutrients, blood-related, oncology, respiratory, HIV antivirals, gastro, anti-diabetic, neuro, and cardiovascular. It provides its products under Orofer XT, Tenectase, Pause, Metpure XL, Vylda, Vitanova, and Proxym brand names. Emcure Pharmaceuticals Limited has a strategic partnership with Novo Nordisk India Pvt Ltd. for the development and commercialization of Poviztra, a semaglut…
Rubicon Research Limited operates as a specialty pharmaceutical company in India, the United States, and internationally. Its primary proprietary technologies for drug delivery comprising RubiSRL for the formulation of sustained release liquids using a combination of ion exchange and membrane diffusion controlled-release technologies; and RubiReten, a gastro-retentive system for drugs with poor solubility and a limited window of absorption. The company develops products in the areas of analgesics/pain management, hypokalemia, gastrointestinal, cardiovascular, skeletal muscle relaxants, metabol…
Emcure Pharmaceuticals has a market capitalisation of ₹35,726 Cr, against ₹27,601 Cr for RUBICON RESEARCH as of 9 Nov 2026, about 1.3 times the size by market cap.
Emcure Pharmaceuticals has a P/E of 38.6 and RUBICON RESEARCH a P/E of 108.9 as of 9 Nov 2026.
Emcure Pharmaceuticals has a return on equity of 19.57% and RUBICON RESEARCH 19.14%.
Emcure Pharmaceuticals's share price is up 67.0% over one year and RUBICON RESEARCH's is up 186.9%.
Emcure Pharmaceuticals reported revenue of ₹2,820 Cr and net profit of ₹325 Cr for Q2 FY27. RUBICON RESEARCH reported revenue of ₹576 Cr and net profit of ₹90 Cr for Q2 FY27. Figures are parsed from each company's exchange filing.
Both are classified under Pharmaceuticals > Biotechnology and Life Sciences > Pharmaceuticals on FinBizNet.
No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.
Data as of 9 Nov 2026. Descriptive market data only — not investment advice.